Literature DB >> 16769899

Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice.

M C Pickering1, J Warren, K L Rose, F Carlucci, Y Wang, M J Walport, H T Cook, M Botto.   

Abstract

Membranoproliferative glomerulonephritis (MPGN) type II (dense deposit disease) is an inflammatory renal disease characterized by electron-dense deposits and complement C3 on the glomerular basement membrane. There is no effective therapy. We investigated the role of C5 activation in a model of MPGN that develops spontaneously in complement factor H-deficient mice (Cfh(-/-)). At 12 months there was a significant reduction in mortality, glomerular cellularity, neutrophil numbers, and serum creatinine levels in Cfh(-/-) mice deficient in C5. Excessive glomerular neutrophil numbers, frequently seen in patients with MPGN during disease flares, were also observed in Cfh(-/-) mice after the administration of an antiglomerular basement membrane antibody. This exaggerated injurious phenotype was absent in Cfh(-/-) mice deficient in C5 but not in Cfh(-/-) mice deficient in C6, indicating a key role for C5 activation in the induction of renal lesions. Importantly, the renal injury was completely reversed in Cfh(-/-) mice pretreated with an anti-murine C5 antibody. These results demonstrate an important role for C5 in both spontaneous MPGN and experimentally induced nephritis in factor H-deficient mice and provide preliminary evidence that C5 inhibition therapy might be useful in human MPGN type II.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16769899      PMCID: PMC1476693          DOI: 10.1073/pnas.0601094103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  46 in total

1.  Accelerated nephrotoxic nephritis is exacerbated in C1q-deficient mice.

Authors:  M G Robson; H T Cook; M Botto; P R Taylor; N Busso; R Salvi; C D Pusey; M J Walport; K A Davies
Journal:  J Immunol       Date:  2001-06-01       Impact factor: 5.422

2.  Complement factor H polymorphism in age-related macular degeneration.

Authors:  Robert J Klein; Caroline Zeiss; Emily Y Chew; Jen-Yue Tsai; Richard S Sackler; Chad Haynes; Alice K Henning; John Paul SanGiovanni; Shrikant M Mane; Susan T Mayne; Michael B Bracken; Frederick L Ferris; Jurg Ott; Colin Barnstable; Josephine Hoh
Journal:  Science       Date:  2005-03-10       Impact factor: 47.728

3.  An inherited defect in the C3 convertase, C3b,Bb, associated with glomerulonephritis.

Authors:  H K Marder; T H Coleman; J Forristal; L Beischel; C D West
Journal:  Kidney Int       Date:  1983-05       Impact factor: 10.612

4.  Protection and injury: the differing roles of complement in the development of glomerular injury.

Authors:  N S Sheerin; T Springall; K Abe; S H Sacks
Journal:  Eur J Immunol       Date:  2001-04       Impact factor: 5.532

5.  Hypocomplementemic glomerulonephritis in an infant and mother. Evidence for an abnormal form of C3.

Authors:  M A Linshaw; F B Stapleton; F E Cuppage; J Forristal; C D West; R D Schreiber; C B Wilson
Journal:  Am J Nephrol       Date:  1987       Impact factor: 3.754

6.  Composition of nephritic factor-generated glomerular deposits in membranoproliferative glomerulonephritis type 2.

Authors:  C D West; D P Witte; A J McAdams
Journal:  Am J Kidney Dis       Date:  2001-06       Impact factor: 8.860

7.  Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H.

Authors:  Matthew C Pickering; H Terence Cook; Joanna Warren; Anne E Bygrave; Jill Moss; Mark J Walport; Marina Botto
Journal:  Nat Genet       Date:  2002-07-01       Impact factor: 38.330

8.  H deficiency in two brothers with atypical dense intramembranous deposit disease.

Authors:  M Levy; L Halbwachs-Mecarelli; M C Gubler; G Kohout; A Bensenouci; P Niaudet; G Hauptmann; P Lesavre
Journal:  Kidney Int       Date:  1986-12       Impact factor: 10.612

Review 9.  Eculizumab (Alexion).

Authors:  Mariana Kaplan
Journal:  Curr Opin Investig Drugs       Date:  2002-07

10.  Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells.

Authors:  L R Benzaquen; A Nicholson-Weller; J A Halperin
Journal:  J Exp Med       Date:  1994-03-01       Impact factor: 14.307

View more
  70 in total

Review 1.  Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets.

Authors:  Pauline L Martin; Peter J Bugelski
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

2.  Eculizumab in Pediatric Dense Deposit Disease.

Authors:  Michiel J S Oosterveld; Mark R Garrelfs; Bernd Hoppe; Sandrine Florquin; Joris J T H Roelofs; L P van den Heuvel; Kerstin Amann; Jean-Claude Davin; Antonia H M Bouts; Pietrik J Schriemer; Jaap W Groothoff
Journal:  Clin J Am Soc Nephrol       Date:  2015-08-27       Impact factor: 8.237

3.  Genetic loci modulating amyloid-beta levels in a mouse model of Alzheimer's disease.

Authors:  Davis Ryman; Yuan Gao; Bruce T Lamb
Journal:  Neurobiol Aging       Date:  2007-04-02       Impact factor: 4.673

Review 4.  Leukocytes in glomerular injury.

Authors:  Stephen R Holdsworth; Peter G Tipping
Journal:  Semin Immunopathol       Date:  2007-10-16       Impact factor: 9.623

5.  Cutting edge: the NLRP3 inflammasome links complement-mediated inflammation and IL-1β release.

Authors:  Federica Laudisi; Roberto Spreafico; Maximilien Evrard; Timothy R Hughes; Barbara Mandriani; Matheswaran Kandasamy; B Paul Morgan; Baalasubramanian Sivasankar; Alessandra Mortellaro
Journal:  J Immunol       Date:  2013-07-01       Impact factor: 5.422

Review 6.  Review: Complement and its regulatory proteins in kidney diseases.

Authors:  Allison M Lesher; Wen-Chao Song
Journal:  Nephrology (Carlton)       Date:  2010-10       Impact factor: 2.506

7.  Molecular mechanisms of chronic kidney transplant rejection via large-scale proteogenomic analysis of tissue biopsies.

Authors:  Aleksey Nakorchevsky; Johannes A Hewel; Sunil M Kurian; Tony S Mondala; Daniel Campbell; Steve R Head; Christopher L Marsh; John R Yates; Daniel R Salomon
Journal:  J Am Soc Nephrol       Date:  2010-01-21       Impact factor: 10.121

8.  Efficacy of Targeted Complement Inhibition in Experimental C3 Glomerulopathy.

Authors:  Marieta M Ruseva; Tao Peng; Melissa A Lasaro; Keith Bouchard; Susan Liu-Chen; Fang Sun; Zhao-Xue Yu; Andre Marozsan; Yi Wang; Matthew C Pickering
Journal:  J Am Soc Nephrol       Date:  2015-06-05       Impact factor: 10.121

9.  Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway.

Authors:  Sanjeev Sethi; Jeffrey D Gamez; Julie A Vrana; Jason D Theis; H Robert Bergen; Peter F Zipfel; Ahmet Dogan; Richard J H Smith
Journal:  Kidney Int       Date:  2009-01-28       Impact factor: 10.612

10.  Anaphylatoxin C5a contributes to the pathogenesis of cisplatin-induced nephrotoxicity.

Authors:  Hao Pan; Zhoujun Shen; Partha Mukhopadhyay; Hua Wang; Pal Pacher; Xuebin Qin; Bin Gao
Journal:  Am J Physiol Renal Physiol       Date:  2009-01-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.